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Supplementary Table 1: Pre and Post Treatment GPNMB Expression 
Tissue Site Baseline  
% Positive 
Intensity Day 21  
% Positive 
Intensity 
Liver 100 3+ 100 3+ 
Liver 100 3+ 100 3+ 
Liver 50 1+ - - 
Breast 0 0 - - 
Liver 0 0 0 0 
Liver 0 0 20 1+ 
Skull base, subcutaneous 100 3+ 100 3+ 
Liver 100 3+ 100 3+ 
Liver 20 1+ 30 1+ 
Liver 0 0 - - 
Liver - - 0 0 
Liver 70 3+ 0 0 
Liver, Subcutaneous 100 2+ 100 3+ 
Eye (primary), Lymph node 80 3+ 100 3+ 
Liver 100 3+ 100 3+ 
Liver 100 2+ 99 3+ 
Liver - - 15 3+ 
Liver 100 3+ 80 3+ 
Subcutaneous 100 3+ 100 3+ 
Subcutaneous 70 3+ 100 3+ 
Subcutaneous 35 2+ 100 3+ 
Eye (primary), Subcutaneous 100 3+ 100 3+ 
Liver 95 3+ 100 3+ 
Liver 0 0 45 2+ 
Liver 0 0 0 0 
Liver 0 0 20 1+ 
Liver 30 2+ 100 3+ 
Liver 100 3+ - - 
Abbreviations: GPNMB: Glycoprotein NMB 
GPNMB expression was analyzed via IHC at baseline and after 1 cycle of GV. A change in GPNMB expression 
greater than 10% was considered a positive signal.  
 
